Stoke Therapeutics: Its Dravet Syndrome Lead Asset Enters The Last Stretch
Stoke Therapeutics Inc STOK
$28.86
▼ -3.93%
($-1.18)
⬇️ Below Yest. Low
🔥 High Short Interest
🗓️ Earnings Next Week
Open
$29.75
Prev Close
$30.04
Day Range
$28.70 – $30.00
52W Range
$12.41 – $40.22
Market Cap
$1.80B
Beta
1.21
EPS (TTM)
$-2.83
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-06-19 |
| Shares Out. | 62,280,000 |
| Website | stoketherapeutics.com/ ↗ |
| Phone | 13025310855 |
| Employees | 170 |
| Revenue | $6.2M |
| Gross Profit | $6.2M |
| Net Income | -$50.0M |
| Free Cash Flow | -$147.7M |
| Total Assets | $443.3M |
| Total Liabilities | $48.4M |
| Equity | $394.9M |
About Stoke Therapeutics Inc
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Stoke Therapeutics Inc is a publicly traded company under the ticker symbol STOK on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-07-01)